Home  /  Resource Library  /  Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapores private insurance payers perspective

Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapores private insurance payers perspective

Study examined the cost effectivenes of CAR T Tisagenlecleucel for treatment of relapsed DLBCL.